Literature DB >> 23416461

The multiple roles for Sox2 in stem cell maintenance and tumorigenesis.

Kuancan Liu1, Baoshun Lin, Meng Zhao, Xiangyue Yang, Min Chen, Anding Gao, Fei Liu, Jianwen Que, Xiaopeng Lan.   

Abstract

The Sry-containing protein Sox2 initially was known to regulate the self-renewal of the mouse and human embryonic stem cells (ESCs). It is also important for the maintenance of stem cells in multiple adult tissues including the brain and trachea, and it is one of the key transcription factors for establishing induced pluripotent stem cells. Recently, overexpression and gene amplification of Sox2 have been associated with the development of squamous cell carcinoma in multiple tissues such as the lung and esophagus. These different roles for Sox2 involve a complicated regulatory networks consisting of microRNAs, kinases and signaling molecules. While the levels of Sox2 are modulated transcriptionally and translationally, post-translational modification is also important for the various functions of Sox2. In clinics, high levels of Sox2 are correlated with poor prognosis and increased proliferation of cancer stem cells. Therefore targeting Sox2 can be potentially explored for a new therapeutic avenue to treat cancers. This review will focus on the different roles for Sox2 in stem cell maintenance and its oncogenic roles in the context of signal transcription and microRNA regulation. We will also review the main upstream and downstream targets of Sox2, which can be potentially used as therapeutic measures to treat cancer with abnormal levels of Sox2.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23416461      PMCID: PMC3871517          DOI: 10.1016/j.cellsig.2013.02.013

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  49 in total

1.  Landscape of the SOX2 protein-protein interactome.

Authors:  Xuefeng Fang; Jae-Geun Yoon; Lisha Li; Yihsuan S Tsai; Shu Zheng; Leroy Hood; David R Goodlett; Gregory Foltz; Biaoyang Lin
Journal:  Proteomics       Date:  2011-01-31       Impact factor: 3.984

2.  SOX2 and CHD7 cooperatively regulate human disease genes.

Authors:  Janusz Puc; Michael G Rosenfeld
Journal:  Nat Genet       Date:  2011-06       Impact factor: 38.330

3.  Transcriptional factor typing with SOX2, HNF4aP1, and CDX2 closely relates to tumor invasion and Epstein-Barr virus status in gastric cancer.

Authors:  Hiroshi Uozaki; Rita Rani Barua; Sun Minhua; Tetsuo Ushiku; Rumi Hino; Aya Shinozaki; Takashi Sakatani; Masashi Fukayama
Journal:  Int J Clin Exp Pathol       Date:  2011-03-01

4.  ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*-mediated suppression of SOX2.

Authors:  Hye-Min Jeon; Young-Woo Sohn; Se-Yeong Oh; Se-Young Oh; Sung-Hak Kim; Samuel Beck; Soonhag Kim; Hyunggee Kim
Journal:  Cancer Res       Date:  2011-05-01       Impact factor: 12.701

5.  SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer.

Authors:  Theresia Wilbertz; Patrick Wagner; Karen Petersen; Ann-Cathrin Stiedl; Veit J Scheble; Sebastian Maier; Markus Reischl; Ralf Mikut; Nasser K Altorki; Holger Moch; Falko Fend; Annette Staebler; Adam J Bass; Matthew Meyerson; Mark A Rubin; Alex Soltermann; Claudia Lengerke; Sven Perner
Journal:  Mod Pathol       Date:  2011-04-01       Impact factor: 7.842

6.  Sox2 uses multiple domains to associate with proteins present in Sox2-protein complexes.

Authors:  Jesse L Cox; Sunil K Mallanna; Xu Luo; Angie Rizzino
Journal:  PLoS One       Date:  2010-11-12       Impact factor: 3.240

7.  Sox2 cooperates with Chd7 to regulate genes that are mutated in human syndromes.

Authors:  Erik Engelen; Umut Akinci; Jan Christian Bryne; Jun Hou; Cristina Gontan; Maaike Moen; Dorota Szumska; Christel Kockx; Wilfred van Ijcken; Dick H W Dekkers; Jeroen Demmers; Erik-Jan Rijkers; Shoumo Bhattacharya; Sjaak Philipsen; Larysa H Pevny; Frank G Grosveld; Robbert J Rottier; Boris Lenhard; Raymond A Poot
Journal:  Nat Genet       Date:  2011-05-01       Impact factor: 38.330

8.  The SOX2 response program in glioblastoma multiforme: an integrated ChIP-seq, expression microarray, and microRNA analysis.

Authors:  Xuefeng Fang; Jae-Geun Yoon; Lisha Li; Wei Yu; Jiaofang Shao; Dasong Hua; Shu Zheng; Leroy Hood; David R Goodlett; Gregory Foltz; Biaoyang Lin
Journal:  BMC Genomics       Date:  2011-01-06       Impact factor: 3.969

9.  MicroRNA-126 inhibits SOX2 expression and contributes to gastric carcinogenesis.

Authors:  Takeshi Otsubo; Yoshimitsu Akiyama; Yutaka Hashimoto; Shu Shimada; Kentaro Goto; Yasuhito Yuasa
Journal:  PLoS One       Date:  2011-01-27       Impact factor: 3.240

10.  Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer.

Authors:  R Xiang; D Liao; T Cheng; H Zhou; Q Shi; T S Chuang; D Markowitz; R A Reisfeld; Y Luo
Journal:  Br J Cancer       Date:  2011-04-05       Impact factor: 7.640

View more
  120 in total

Review 1.  Personalized and targeted therapy of esophageal squamous cell carcinoma: an update.

Authors:  Yongjing Liu; Zhaohui Xiong; Andrea Beasley; Thomas D'Amico; Xiaoxin Luke Chen
Journal:  Ann N Y Acad Sci       Date:  2016-07-11       Impact factor: 5.691

2.  The initial establishment and epithelial morphogenesis of the esophagus: a new model of tracheal-esophageal separation and transition of simple columnar into stratified squamous epithelium in the developing esophagus.

Authors:  Jianwen Que
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2015-02-27       Impact factor: 5.814

Review 3.  Two Sides of the Same Coin: The Role of Developmental pathways and pluripotency factors in normal mammary stem cells and breast cancer metastasis.

Authors:  M U J Oliphant; Deguang Kong; Hengbo Zhou; M T Lewis; H L Ford
Journal:  J Mammary Gland Biol Neoplasia       Date:  2020-04-22       Impact factor: 2.673

4.  Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells.

Authors:  Upal Basu-Roy; N Sumru Bayin; Kirk Rattanakorn; Eugenia Han; Dimitris G Placantonakis; Alka Mansukhani; Claudio Basilico
Journal:  Nat Commun       Date:  2015-04-02       Impact factor: 14.919

5.  Expression of microRNA 638 and sex-determining region Y-box 2 in hepatocellular carcinoma: Association between clinicopathological features and prognosis.

Authors:  Weikang Ye; Jieke Li; Guan Fang; Xiupeng Cai; Yan Zhang; Chaojun Zhou; Lei Chen; Wenjun Yang
Journal:  Oncol Lett       Date:  2018-03-08       Impact factor: 2.967

6.  G1 cyclins link proliferation, pluripotency and differentiation of embryonic stem cells.

Authors:  Lijun Liu; Wojciech Michowski; Hiroyuki Inuzuka; Kouhei Shimizu; Naoe Taira Nihira; Joel M Chick; Na Li; Yan Geng; Alice Y Meng; Alban Ordureau; Aleksandra Kołodziejczyk; Keith L Ligon; Roderick T Bronson; Kornelia Polyak; J Wade Harper; Steven P Gygi; Wenyi Wei; Piotr Sicinski
Journal:  Nat Cell Biol       Date:  2017-02-13       Impact factor: 28.824

7.  Sex-determining region Y-related high mobility group box (SOX)-2 is overexpressed in cervical squamous cell carcinoma and contributes cervical cancer cell migration and invasion in vitro.

Authors:  Xiaohan Chang; Jing Zhang; Chenglin Huang; Xiaoao Pang; Qingshuang Luo; Huijie Zhang; Shulan Zhang
Journal:  Tumour Biol       Date:  2015-05-03

8.  LncRNA SOX2OT affects cervical cancer cell growth, migration and invasion by regulating SOX2.

Authors:  Xiaohan Chang; Huijie Zhang; Qing Yang; Li Pang
Journal:  Cell Cycle       Date:  2020-04-14       Impact factor: 4.534

9.  The FBXW2-MSX2-SOX2 axis regulates stem cell property and drug resistance of cancer cells.

Authors:  Yuan Yin; Chuan-Ming Xie; Hua Li; Mingjia Tan; Guoan Chen; Rachel Schiff; Xiufang Xiong; Yi Sun
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-23       Impact factor: 11.205

Review 10.  Biomarkers in retinoblastoma.

Authors:  Jie Sun; Hui-Yu Xi; Qing Shao; Qing-Huai Liu
Journal:  Int J Ophthalmol       Date:  2020-02-18       Impact factor: 1.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.